Sihuan Pharmaceutical Holdings Group (HK:0460) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Sihuan Pharmaceutical Holdings Group Ltd. has secured an exclusive deal with Cellontech Korea to distribute CartiZol, a novel intra-articular collagen injection, in mainland China, marking a significant potential in the Chinese osteoarthritis market given the absence of similar approved treatments. The agreement follows a previous exclusive arrangement for porcine collagen medical aesthetic filler products and reinforces Sihuan Pharmaceutical’s commitment to expanding its medical aesthetics and biopharmaceutical portfolio. Cellontech Korea, known for its pioneering regenerative medical products, has been a key partner for Sihuan Pharmaceutical in its strategy to become a leader in China’s medical aesthetics and biopharma sectors.
For further insights into HK:0460 stock, check out TipRanks’ Stock Analysis page.
